Angiographic outcomes with early eptifibatide therapy in non-ST-segment elevation acute coronary syndrome (from the EARLY ACS Trial).
暂无分享,去创建一个
R. Califf | R. Giugliano | E. Braunwald | L. Newby | P. Armstrong | F. Van de Werf | A. Bagai | R. Harrington | G. Montalescot | C. Gibson | V. Kunadian | C. Zorkun | Jianping Guo | L. Newby | J. Guo | R. Califf | P. Armstrong | C. Gibson
[1] R. Califf,et al. Association between angiographic complications and clinical outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention: an EARLY ACS (Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome) angiographic substudy. , 2012, JACC. Cardiovascular interventions.
[2] G. Stone,et al. Intraprocedural thrombotic events during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes are associated with adverse outcomes: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. , 2012, Journal of the American College of Cardiology.
[3] R. Califf,et al. Association between Angiographic Complications and Clinical Outcomes among Patients with Acute Coronary Syndrome undergoing Percutaneous Coronary Intervention: An EARLY ACS Angiographic Substudy , 2012 .
[4] V. Hasselblad,et al. Upstream Use of Small-Molecule Glycoprotein IIb/IIIa Inhibitors in Patients With Non–ST-Segment Elevation Acute Coronary Syndromes: A Systematic Overview of Randomized Clinical Trials , 2011, Circulation. Cardiovascular quality and outcomes.
[5] H. Suryapranata,et al. Meta-analysis of randomized trials of glycoprotein IIb/IIIa inhibitors in high-risk acute coronary syndromes patients undergoing invasive strategy. , 2011, The American journal of cardiology.
[6] F. Prati,et al. Evaluation of infarct-related coronary artery patency and microcirculatory function after facilitated percutaneous primary coronary angioplasty: the FINESSE-ANGIO (Facilitated Intervention With Enhanced Reperfusion Speed to Stop Events-Angiographic) study. , 2010, JACC. Cardiovascular interventions.
[7] R. Califf,et al. Early versus delayed, provisional eptifibatide in acute coronary syndromes. , 2009, The New England journal of medicine.
[8] Claes Held,et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.
[9] W. Gibson,et al. Intracoronary pharmacotherapy in the management of coronary microvascular dysfunction , 2008, Journal of Thrombosis and Thrombolysis.
[10] G. Biondi-Zoccai,et al. Early glycoprotein IIb–IIIa inhibitors in primary angioplasty (EGYPT) cooperation: an individual patient data meta-analysis , 2008, Heart.
[11] E. Antman,et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.
[12] L. Newby,et al. Timing of glycoprotein IIb/IIIa inhibitor use and outcomes among patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (results from CRUSADE). , 2007, The American journal of cardiology.
[13] J. Ware,et al. Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. , 2007, JAMA.
[14] R. Califf,et al. The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndro , 2005, American heart journal.
[15] G. Montalescot,et al. Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis. , 2004, JAMA.
[16] A. Yeung,et al. Adjunctive Platelet Glycoprotein IIb/IIIa Receptor Inhibition With Tirofiban Before Primary Angioplasty Improves Angiographic Outcomes: Results of the TIrofiban Given in the Emergency Room before Primary Angioplasty (TIGER-PA) Pilot Trial , 2003, Circulation.
[17] E. Braunwald,et al. Relationship of the TIMI Myocardial Perfusion Grades, Flow Grades, Frame Count, and Percutaneous Coronary Intervention to Long-Term Outcomes After Thrombolytic Administration in Acute Myocardial Infarction , 2002, Circulation.
[18] M. Morice,et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. , 2001, The New England journal of medicine.
[19] E. Antman,et al. Combination Therapy With Abciximab Reduces Angiographically Evident Thrombus in Acute Myocardial Infarction: A TIMI 14 Substudy , 2001, Circulation.
[20] E. Braunwald,et al. TIMI frame count: a quantitative method of assessing coronary artery flow. , 1996, Circulation.
[21] H. S. Mueller,et al. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. , 1985, The New England journal of medicine.